Genomic Instability and Gene Therapeutics in Neurological Diseases

With the rapidly emerging new tools including genomics, bioinformatics, metabolomics and proteomic analysis and new powerful editing tools such as CRISPR/CAS9 we are getting closer to more defined understanding of the complex cellular pathways underpinning neurodegeneration, which underlie many debilitating pathological and age-associated neurological demise. This is a great opportunity to assemble a rich programme of international speakers to address the latest advances from basic research to clinical applications in disorders of the central nervous system. The conference will primarily focus on amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD), spinal muscular atrophy (SMA), Alzheimer’s disease/dementia, and repeat expansion disorders with translational spin focussing on recent advances in gene based-therapeutics. Our aim is to share ideas, exchange knowledge and inspire young and established investigators to embrace new research directions. The conference will be chaired by Sherif El-Khamisy and Mimoun Azzouz together with leaders in the field of neurodegeneration. The conference will host many established speakers in the field and a number of oral presentations will be selected from submitted abstracts. For sponsorship opportunities contact Fusion Conferences Please note registration fees include fixed accommodation (5, 6 and 7 March 2018), an all-inclusive food and beverage package and conference attendance.

When is Genomic Instability and Gene Therapeutics in Neurological Diseases?

The next dates haven't been confirmed. The last edition we have on record was 5–9 Mar 2018.

Where is it held?

The last edition we have was at Fiesta Americana Hotel, Cancun, Mexico.

Who organises it?

Fusion Conferences.